|
1
|
Socinski MA: Cytotoxic chemotherapy in
advanced non-small cell lung cancer: a review of standard treatment
paradigms. Clin Cancer Res. 10:4210–4214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fellner S, Bauer B, Miller DS, et al:
Transport of paclitaxel (Taxol) across the blood-brain barrier in
vitro and in vivo. J Clin Invest. 110:1309–1318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walle UK and Walle T: Taxol transport by
human intestinal epithelial Caco-2 cells. Drug Metab Dispos.
26:343–346. 1998.PubMed/NCBI
|
|
4
|
Huizing MT, Giaccone G, van Warmerdam LJ,
et al: Pharmacokinetics of paclitaxel and carboplatin in a
dose-escalating and dose-sequencing study in patients with
non-small cell lung cancer. The European Cancer Centre. J Clin
Oncol. 15:317–329. 1997.PubMed/NCBI
|
|
5
|
Sonnichsen DS, Hurwitz CA, Pratt CB,
Shuster JJ and Relling MV: Saturable pharmacokinetics and
paclitaxel pharmacodynamics in children with solid tumors. J Clin
Oncol. 12:532–538. 1994.PubMed/NCBI
|
|
6
|
Dai D, Zeldin DC, Blaisdell JA, Chanas B,
Coulter SJ, Ghanayem BI and Goldstein JA: Polymorphisms in human
CYP2C8 decrease metabolism of the anticancer drug paclitaxel and
arachidonic acid. Pharmacogenetics. 11:597–607. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harris JW, Rahman A, Kim BR, Guengerich FP
and Collins JM: Metabolism of taxol by human hepatic microsomes and
liver slices: participation of cytochrome P450 3A4 and an unknown
P450 enzyme. Cancer Res. 54:4026–4035. 1994.PubMed/NCBI
|
|
8
|
Malingré MM, Beijnen JH and Rosing H:
Co-administration of GF120918 significantly increases the systemic
exposure to oral paclitaxel in cancer patients. Br J Cancer.
84:42–47. 2001.PubMed/NCBI
|
|
9
|
Cordon-Cardo C, O’Brien JP, Boccia J, et
al: Multidrug-resistance gene (P-glycoprotein) is expressed by
endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci
USA. 86:695–698. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schinkel AH, Smit JJ and van Tellingen O:
Disruption of the mouse mdr1a P-glycoprotein gene leads to a
deficiency in the blood-brain barrier and to increased sensitivity
to drugs. Cell. 77:491–502. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Henningsson A, Marsh S and Loos WJ:
Association of CYP2C8, CYP3A4, CYP3A5 and ABCB1 polymorphisms with
the pharmacokinetics of paclitaxel. Clin Cancer Res. 11:8097–8104.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sissung TM, Mross K, Steinberg SM,
Behringer D, Figg WD, Sparreboom A and Mielke S: Association of
ABCB1 alleles with paclitaxel-mediated peripheral neuropathy and
neutropenia. Eur J Cancer. 42:2893–2896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cavalli SA, Hirata MH and Hirata RD:
Detection of MboII polymorphism at the 5′ promoter region of
CYP3A4. Clin Chem. 47:348–351. 2001.
|
|
14
|
Kim DH, Park JY, Sohn SK, et al: Multidrug
resistance-1 gene polymorphisms associated with treatment outcomes
in de novo acute myeloid leukemia. Int J Cancer. 118:2195–2201.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spratlin J and Sawyer MB: Pharmacogenetics
of paclitaxel metabolism. Crit Rev Oncol Hematol. 61:222–229. 2007.
View Article : Google Scholar
|
|
16
|
Lamba JK, Lin YS, Schuetz EG and Thummel
KE: Genetic contribution to variable human CYP3A-mediated
metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gréen H, Söderkvist P, Rosenberg P,
Horvath G and Peterson C: Mdr-1 single nucleotide polymorphisms in
ovarian cancer tissue: G2677T/A correlates with response to
paclitaxel chemotherapy. Clin Cancer Res. 12:854–859.
2006.PubMed/NCBI
|
|
18
|
Bahadur N, Leathart JB, Mutch E, et al:
CYP2C8 polymorphisms in Caucasians and their relationship with
paclitaxel 6alpha-hydroxylase activity in human liver microsomes.
Biochem Pharmacol. 64:1579–1589. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006.
|
|
20
|
Hoffmeyer S, Burk O, von Richter O, et al:
Functional polymorphisms of the human multidrug-resistance gene:
multiple sequence variations and correlation of one allele with
P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci
USA. 97:3473–3478. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kafka A, Sauer G, Jaeger C, Grundmann R,
Kreienberg R, Zeillinger R and Deissler H: Polymorphism C3435T of
the MDR-1 gene predicts response to preoperative chemotherapy in
locally advanced breast cancer. Int J Oncol. 22:1117–1121.
2003.PubMed/NCBI
|
|
22
|
Siddiqui A, Kerb R, Weale ME, et al:
Association of multidrug resistance in epilepsy with a polymorphism
in the drug-transporter gene ABCB1. N Engl J Med. 348:1442–1448.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cascorbi I, Gerloff T, Johne A, et al:
Frequency of single nucleotide polymorphisms in the P-glycoprotein
drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther.
69:169–174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Green H: Pharmacogenomics of importance
for paclitaxel chemotherapy. Pharmacogenomics. 9:671–674. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Keshava C, McCanlies EC and Weston A:
CYP3A4 poly-morphisms – potential risk factors for breast and
prostate cancer: a HuGE review. Am J Epidemiol. 160:825–841.
2004.
|
|
26
|
Rodríguez-Antona C, Sayi JG, Gustafsson
LL, Bertilsson L and Ingelman-Sundberg M: Phenotype-genotype
variability in the human CYP3A locus as assessed by the probe drug
quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res
Commun. 338:299–305. 2005.PubMed/NCBI
|
